THE Europeans Medicines Agency (EMA) has recommended a change in the composition of Trixeo Aerosphere and Riltrava Aerosphere (budesonide, glycopyrronium, formoterol fumarate dihydrate) inhaled medicines used to treat COPD.
The existing gas propellant has been replaced with a low global warming potential (GWP) alternative.
The new low GWP alternative propellant has a 1,000-fold reduction in global warming potential and has similar safety and efficacy as the current gas.
High GWP gases, including hydrofluorocarbon gases used in other inhaled medicines for treating respiratory diseases, are being phased out for environmental reasons, in line with current EU policies.
The above article was sent to subscribers in Pharmacy Daily's issue from 28 Jul 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 28 Jul 25
